四川百利天恒药业股份有限公司关于刊发H股招股说明书、H股发行价格区间及H股香港公开发售等事宜的公告

Core Viewpoint - Sichuan Baili Tianheng Pharmaceutical Co., Ltd. is in the process of issuing H-shares and listing on the Hong Kong Stock Exchange, with the aim of expanding its capital base and enhancing its market presence [1][4]. Group 1: H-share Issuance Process - The company submitted its application for H-share issuance to the Hong Kong Stock Exchange on July 10, 2024, and has since made several resubmissions in accordance with regulatory requirements [2]. - The China Securities Regulatory Commission confirmed the company's overseas issuance and listing on December 11, 2024, providing necessary regulatory approval [3]. - The Hong Kong Stock Exchange's listing committee reviewed the company's application on December 19, 2024, marking a significant step in the listing process [3]. Group 2: H-share Offering Details - The total number of H-shares to be issued is 8,634,300, with 863,500 shares allocated for public offering in Hong Kong, representing approximately 10% of the total offering [5]. - The price range for the H-share issuance is preliminarily set between HKD 347.50 and HKD 389.00, with the public offering expected to commence on November 7, 2025, and conclude on November 12, 2025 [5]. - The H-shares are anticipated to be listed and commence trading on the Hong Kong Stock Exchange on November 17, 2025 [5].